Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia.

Abstract

OBJECTIVES:

Young adults with acute myeloid leukemia (AML) often fail to achieve permanent complete remission (CR) and frequently relapse, indicating an urgent need to explore effective salvage therapies. Recent advances in AML treatment have been attributed to the combination of the B-cell lymphoma 2 (Bcl-2) inhibitor venetoclax (VEN) with hypomethylating agents (HMAs); however, the use of this combination in young adults with relapsed or refractory (R/R) AML has not been reported.

METHODS:

We retrospectively examined 31 young patients with R/R AML treated with VEN plus an HMA. We evaluated the demographic data, cytogenetic characteristics, AML types, response rates, and transplantation-related data for the patients in our cohort.

RESULTS:

The combination of VEN + HMA yielded a CR rate of 48.4%. The most prominent hematologic adverse event was neutropenia, which occurred in all patients, with 90.3% of cases being grade ≥3. Non-hematologic toxicities were relatively mild and infrequent, with an incidence of 45.2%. More than half of the patients with sustained CR had received an allogeneic hematopoietic stem cell transplantation (allo-HSCT), of whom two died of transplant-related complications.

CONCLUSION:

Our results showed that the combination of VEN + HMA appeared to be a highly effective and well-tolerated salvage therapy option for young patients with R/R AML, enabling more young patients to proceed to potentially curative allo-HSCT. However, additional, well-designed studies with larger numbers of patients are required to confirm the advantages of VEN + HMA in this population.

• Authors: Xuezhu Xu, Rui Liu, Aili He, Fangxia Wang
• Journal: Hematology (Amsterdam, Netherlands) (Hematology) Vol. 28 Issue 1 Pg. 2265206 (Dec 2023) ISSN: 1607-8454 [Electronic] England
• PMID: 37796109 (Publication Type: Journal Article)

Chemical References

• venetoclax
• Antineoplastic Agents
• Bridged Bicyclo Compounds, Heterocyclic

Topics

• Humans
• Young Adult
• Retrospective Studies
• Antineoplastic Agents (therapeutic use)
• Bridged Bicyclo Compounds, Heterocyclic (adverse effects)
• Leukemia, Myeloid, Acute (pathology)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects)